5Pickerill KE, Paladino JA, Schentag JJ. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy, 2000,20:417-428.
6Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-aquired pneumonia.Diagnosis,assessment of severity, antimicrobial therapy, and provention. Am J Respir Crit Care Med, 2001,163:1730-1754.
7Niederman MS. Treatment of respiratory in fections with quinolones. In: An drole V, editor, The quinolones, 2nd edition. San Diego. CA: McGraw-Hill,1998.229-250.
8Bertino J Jr, Fish D. The safety profile of the fluoroquinolones. Clin Ther, 2000, 22:798-817.
9Zuckerman JM, Kaye KM. The newer macrolides. Azithromycin and clarithromycin. Infect Dis Clin North Am,1995,9:713-745.
10Felmingham D,Grüneberg & Alexander Project Group. Alexander Project in Europe: Decreased Susceptibility of Isolates of Stretococcus pneumoniae to Macrolides During the Perid 1992-2000. 12th ECCMID, Milan,2002. 1113.
